Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

SML0132

Sigma-Aldrich

Lanreotide acetate

≥98% (HPLC)

Sinônimo(s):

3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate, Angiopeptin acetate, BIM-23014C

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C54H69N11O10S2 · xC2H4O2
Número CAS:
127984-74-1
Peso molecular:
1096.32 (free base basis)
Código UNSPSC:
12352200
ID de substância PubChem:
329825182
NACRES:
NA.25

Nível de qualidade

100

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to off-white

Condições de expedição

wet ice

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

CC(O)=O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@H](N)Cc5ccc6ccccc6c5

InChI

1S/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)/t30-,38-,40+,41+,42-,43+,44?,45+,46+;/m1./s1

chave InChI

DEXPIBGCLCPUHE-HPDHVNDUSA-N

Aplicação

Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice.

Ações bioquímicas/fisiológicas

Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors.
Octapeptide somatostatin analog; sst2 somatostatin receptor agonist; Antineoplastic

Pictogramas

Health hazard
GHS08

Palavra indicadora

Warning

Frases de perigo

H361

Declarações de precaução

P281

Classificações de perigo

Repr. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
096M4745V
104M4712V
091M4723V

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 4

1 of 4

Oritavancin diphosphate ≥97% (HPLC)

Sigma-Aldrich

SML1586

Oritavancin diphosphate

Romidepsin ≥98% (HPLC)

Sigma-Aldrich

SML1175

Romidepsin

Leuprolide acetate salt ≥98% (HPLC)

Sigma-Aldrich

L0399

Leuprolide acetate salt

Daptomycin cyclic lipopeptide antibiotic

Sigma-Aldrich

D2446

Daptomycin

Lucas Sidéris et al.
The oncologist, 17(6), 747-755 (2012-05-26)
For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect
Nancy M Gardner-Roehnelt
Clinical journal of oncology nursing, 16(1), 56-64 (2012-02-03)
Although neuroendocrine tumors (NETs) have been recognized as a family of complex malignancies since 1907, major progress has been made only in the past 20 years in understanding and managing the disease. The detection and reported incidence of NETs have
Christos Toumpanakis et al.
Seminars in oncology, 40(1), 56-68 (2013-02-09)
Somatostatin analogs (SA) are the standard of care for controlling symptoms of patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). SA control symptoms in more than 70% of patients with carcinoid syndrome. Similar results are obtained in patients with functional, hormone-secreting
Martyn E Caplin et al.
The New England journal of medicine, 371(3), 224-233 (2014-07-12)
Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced
Omid Fotouhi et al.
The Journal of clinical endocrinology and metabolism, 101(10), 3616-3627 (2016-07-28)
Somatostatin analogs are established in the treatment of neuroendocrine tumors (NETs) including small intestinal NET; however, the molecular mechanisms are not well known. Here, we examined the direct effects of lanreotide in NET cell line models. The cell lines HC45
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica